EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant

A M Onnekink iD, D C F Klatte, J E van Hooft, S H van den Berg, S M S van der Zwaan, R van Doorn, S C H Hinnen, T P Potjer, E M A Bleiker, M E van Leerdam

Familial Cancer · 2024

DOI: 10.1007/s10689-024-00401-3 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Familial Cancer, 2024. Verfasst von A M Onnekink und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands. a.m.onnekink@lumc.…. Hauptthemen laut MEDLINE: Genetic Testing, Family Planning Services, Preimplantation Diagnosis, Germ-Line Mutation. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Individuals with a germline CDKN2A pathogenic variant (PV) have a highly increased life time risk of melanoma and pancreatic cancer. This cross-sectional study assessed the attitudes among toward genetic testing, family planning, and preimplantation genetic testing (PGT) in confirmed CDKN2A PV carriers and individuals with a 50% risk of the PV (at-risk carriers) using of a one-time questionnaire. A total of 537 individuals were screened for eligibility, of whom 208 of 366 (57%) confirmed carriers (56% female, median age 54 years [IQR 46–63]) and 39 of 171 (23%) at-risk carriers (59% female, median age of 26 years [IQR 22–32]) participated in the study. Primary motivations for genetic testing were to gain control over their personal and children’s cancer risk, as well as increasing cancer surveillance practices. In contrast, concerns about obtaining a mortgage and life insurance were frequently cited as reasons for postponing genetic testing. Family planning decisions remained largely unaffected in both confirmed and at-risk carriers; however, the majority of confirmed carriers were still unaware of their familial or personal cancer risk when starting a family. More than 60% of the participants were unfamiliar with PGT and only a minority (19% of confirmed carriers and 10% of at-risk carriers) would be open to considering PGT as a reproductive option. This study found different attitudes toward genetic testing, family planning, and PGT among individuals affected by the CDKN2A PV. Understanding these different attitudes can help clinicians to address the complexities surrounding these issues, especially for younger individuals facing difficult decisions about the timing of genetic testing, family planning, and the potential use of assisted reproductive options.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Genetic TestingFamily Planning ServicesPreimplantation DiagnosisGerm-Line MutationGenetic Predisposition to DiseaseCyclin-Dependent Kinase Inhibitor p16HumansFemaleMiddle AgedAdultMaleCross-Sectional StudiesYoung AdultMelanomaHealth Knowledge, Attitudes, PracticeSurveys and QuestionnairesPancreatic NeoplasmsCyclin-Dependent Kinase Inhibitor p18Pregnancy

Substanzen

Cyclin-Dependent Kinase Inhibitor p16CDKN2A protein, humanCyclin-Dependent Kinase Inhibitor p18

Autor:innen und Institutionen

  • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands. a.m.onnekink@lumc.nl.
  • Department of Gastroenterology and Hepatology, Leiden University Medical Center, Albinusdreef 2, Leiden, 2333 ZA, The Netherlands.
  • Department of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.
  • Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Psycho-Oncology, Leiden University Medical Center, Leiden, the Netherlands.
  • Department of Medical Psychology, Spaarne Gasthuis, Haarlem, the Netherlands.

ORCID-Profile: A M Onnekink

Zitieren

APA

Onnekink, A. M., Klatte, D. C. F., van Hooft, J. E., van den Berg, S. H., van der Zwaan, S. M. S., van Doorn, R., Hinnen, S. C. H., Potjer, T. P., Bleiker, E. M. A., & van Leerdam, M. E. (2024). Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant. Familial Cancer. https://doi.org/10.1007/s10689-024-00401-3

Vancouver

Onnekink AM, Klatte DCF, van Hooft JE, van den Berg SH, van der Zwaan SMS, van Doorn R, et al. Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant. Familial Cancer. 2024. doi:10.1007/s10689-024-00401-3

BibTeX
@article{Onnekink2024,
  author = {Onnekink, A M and Klatte, D C F and van Hooft, J E and van den Berg, S H and van der Zwaan, S M S and van Doorn, R and Hinnen, S C H and Potjer, T P and Bleiker, E M A and van Leerdam, M E},
  title = {Attitudes toward genetic testing, family planning and preimplantation genetic testing in families with a germline CDKN2A pathogenic variant},
  journal = {Familial Cancer},
  year = {2024},
  doi = {10.1007/s10689-024-00401-3}
}
Kostenlos starten →